Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Reported net loss of $4.4 million for Q3 fiscal 2026.
Cash and cash equivalents of $10.6 million, providing runway into Q3 2026.
MDNA11 achieved 36% objective response rate in monotherapy and 43% with pembrolizumab.
Expanded clinical trials for MDNA11 and MDNA113 programs.
Advancing MDNA113 through IND-enabling studies, planning IND filing in H2 2026.
To present updated data on bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit.
Earnings announced on February 12 or 13, 2026.